Fatal Adverse Events with Molecular Targeted Agents Treating Advanced Hepatocellular Carcinoma

Sep 20, 2018 | Carcinoma, Fatal Adverse Events, Hepatocellular Carcinoma, Oncology

As reported in Dovepress, Clinicians should be aware of the risks of FAEs during the administration of MTAs in advanced HCC patients, especially for patients with abnormal liver function. However, the use of sorafenib remains justified in its approved indications due to their potential survival benefits and limited toxicities.

  • Department of Infectious Diseases, Yiwu Central Hospital, Yiwu, China
  • The First Hospital of Nanchang, Nanchang, China; 3Gastroenterology Department, Jinhua Central Hospital, Jinhua, China


Pin It on Pinterest